Hormone receptor (HR)-positive / HER2-negative breast cancer is the most prevalent breast cancer subtype. Treatment decisions are influenced by disease stage, genetic test score, menopausal status, resectability, site of metastasis, and prior treatment received. The FDA approval of three CDK4/6 inhibitors in the metastatic setting (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio) has changed physicians’ prescribing behavior and created new dynamics in treatment sequencing. Furthermore, the FDA approvals of two PARP inhibitors (AstraZeneca’s Lynparza and Pfizer’s Talzenna) for metastatic germline BRCA-mutation-positive, HER2-negative (including HR-positive) breast cancer patients, as well as one PI3K inhibitor (Novartis’s Piqray) for advancedPIK3CA-mutation-positive, HR-positive / HER2-negative breast cancer have provided additional treatment options for this patient subgroup.
- How are HR-positive / HER2-negative patients mapped in terms of menopausal status, risk of recurrence, speed of disease progression, and metastasis site?
- What are physicians’ standard treatment practices for early-stage and first- to fourth-line therapy for metastatic HR-positive / HER2-negative breast cancer?
- What are the key drivers and obstacles determining current prescribing for CDK4/6 inhibitors in HR-positive / HER2-negative metastatic breast cancer? How do physicians differentiate between the three CDK4/6 inhibitors?
- Where do PARP and PI3K inhibitors fit in the treatment algorithm for HR-positive / HER2-negative breast cancer?
Current Treatment: Physician insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
- Breast Cancer - Current Treatment - Detailed, Expanded Analysis (US)
- Current Treatment: Physicians Insights - Hormon Receptor-Positive, HER2-Negative Breast Cancer (US) (June 2020)
Author(s): Angela Diana
Angela Diana is an analyst on the Oncology team at Decision Resources Group. Prior to this role, she received a PhD in radiation oncology from the University of Oxford with a thesis focused on better understanding the effects of radiotherapy on the tumor microenvironment. Her project was funded by the EU's Horizon 2020 research and innovation programme and awarded with a Marie-Sklodowska Curie grant. Previously, she was working as a research assistant at Stemgen, a biotech company focused on developing stem cell treatments for cancer and neurodegenerative diseases. She also holds an MSc and a BSc from the University of Study of Milan, Italy